age-related macular degeneration with subfoveal CNV
Ophthalmology · 2005–2020
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| brolucizumab Treatment of subfoveal choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD). | Mar 2020 | Not recommended | none received |
| verteporfin Treatment of subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration where the CNV is composed predominantly (≥50%) of… | Nov 2005 | Recommended with restriction | no section in document |
What the PBS pays
$1M in government benefit over 2024–25, across 1,431 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| brolucizumab | $1.5M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.